Credits Available: 4.25 AMA PRA Category 1 Credit™/ MOC Points

Description: This dynamic course focuses on the exchange of best practices regarding the use of bispecifics in patients with R/R DLBCL including patient eligibility. Through this interactive, small-group activity, participants will review brief modules and patient cases to identify signs and symptoms of toxicities experienced while receiving treatment with bispecific antibodies for R/R DLBCL and also integrate protocols to manage CRS and ICANS effectively when managing patients. The group will gather for a live discussion via Zoom to share and exchange ideas on this topic.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse, Nurse Practitioner, Pharmacist, Physician Assistant
Target Specialties: Hematology, Hematology/Oncology, Oncology

Natalie Grover

University of North Carolina School of Medicine
Associate Professor

I am a lymphoma physician and clinical director of the cellular therapy program at UNC. I'm looking forward to connecting with the other members of the group.